🔗 Visit the ClinicalTrials.gov page for NCT01175213
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. | AAPS J | 2015 | 0.77 |
| 2 | Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. | J Clin Immunol | 2016 | 0.75 |
| 3 | Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. | AAPS J | 2015 | 0.75 |
| 4 | Subcutaneous immunoglobulin: facilitated infusion and advances in administration. | Clin Exp Immunol | 2014 | 0.75 |
| 5 | Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. | Immunotherapy | 2021 | 0.75 |